Before the FOOD AND DRUG ADMINISTRATION Washington, D.C.

In re:

Docket No. 2004Q-0144; Petition for Health Claims: 1) Chromium picolinate may reduce the risk of insulin resistance. 2) Chromium picolinate may reduce the risk of cardiovascular disease when caused by insulin resistance. 3) Chromium picolinate may reduce abnormally elevated blood sugar levels. 4) Chromium picolinate may reduce the risk of cardiovascular disease when caused by abnormally elevated blood sugar levels. 5) Chromium picolinate may reduce the risk of type 2 diabetes. 6) Chromium picolinate may reduce the risk of cardiovascular disease when caused by type 2 diabetes. 7) Chromium picolinate may reduce the risk of retinopathy when caused by abnormally high blood sugar levels. 8) Chromium picolinate may reduce the risk of kidney disease when caused by abnormally high blood sugar levels.

SUPPLEMENTAL SUBMISSION

Nutrition 21, Inc. ("Petitioner") hereby supplements the record in the above-referenced proceeding with the attached scientific references consisting of two articles studying chromium picolinate supplementation that were published after the petition was submitted.

Respectfully submitted,

NUTRITION 21, INC.,

Jonathan W. Emord Andrea G. Ferrenz

Its Counsel

Jonathan W. Emord Andrea G. Ferrenz Emord & Associates, P.C. 1800 Alexander Bell Dr. Suite 200 Reston, VA 20191 (202) 466-6937

Fax: (202) 466-6938

Date submitted: November 12, 2004